Polymer–lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells

QR Code

Polymer–lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells

Jun Li,1,* Wenqing Xu,2,* Xiaoli Yuan,3,* Huaiwen Chen,3 Hao Song,1,4 Bingquan Wang,5 Jun Han5 1College of Pharmacy, Liaocheng University, Liaocheng, Shandong, 2Railway Police College, Zhengzhou, 3Department of Cadre Health Care, Nanjing General Hospital of Nanjing Military Command, Nanjing, Jiangs...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Li J, Xu WQ, Yuan XL, Chen HW, Song H, Wang BQ, Han J
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2017
Sujets:	Nanoparticles Breast cancer Cancer stem cells Salinomycin HER2 Medicine (General) R5-920
Accès en ligne:	https://doaj.org/article/ee288ab9e1644ebf9210f26d70a1942d
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Co-Delivery of Docetaxel and Salinomycin to Target Both Breast Cancer Cells and Stem Cells by PLGA/TPGS Nanoparticles
par: Gao J, et autres
Publié: (2019)

Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
par: Diana B. Peckys, et autres
Publié: (2021)

Synthesis and Characterization of Salinomycin-Loaded High-Density Lipoprotein and Its Effects on Cervical Cancer Cells and Cervical Cancer Stem Cells
par: Yin X, et autres
Publié: (2021)

HER2/neu Status in Breast Cancer Specimens: Comparison of Immunohistochemistry (IHC) and Fluorescence in situ Hybridization (FISH) Methods
par: Saglican,Yesim, et autres
Publié: (2015)

Enhanced and Prolonged Antitumor Effect of Salinomycin-Loaded Gelatinase-Responsive Nanoparticles via Targeted Drug Delivery and Inhibition of Cervical Cancer Stem Cells
par: Wang Q, et autres
Publié: (2020)

Utility of Serum HER-2/ neu in Prediction of Tissue HER-2 /neu Status of Primary Breast Cancer
par: Maral Mokhtari, et autres
Publié: (2021)

Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches
par: Ayoub NM, et autres
Publié: (2019)

Salinomycin-Loaded Small-Molecule Nanoprodrugs Enhance Anticancer Activity in Hepatocellular Carcinoma
par: Wang J, et autres
Publié: (2020)

Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments
par: Serafin Morales, et autres
Publié: (2021)

Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
par: Jagosky M, et autres
Publié: (2021)

Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer
par: Board Editorial
Publié: (2021)

Differential Second Primary Malignancy Occurrence After Breast Cancer According to HER2 Status: A Population-Based Study
par: Lin X, et autres
Publié: (2021)

Combination of salinomycin and silver nanoparticles enhances apoptosis and autophagy in human ovarian cancer cells: an effective anticancer therapy
par: Zhang XF, et autres
Publié: (2016)

Prognostic factors and survival prediction in HER2‐positive breast cancer with bone metastases: A retrospective cohort study
par: Xiaoshuang Lyu, et autres
Publié: (2021)

Targeted Fe-doped silica nanoparticles as a novel ultrasound–magnetic resonance dual-mode imaging contrast agent for HER2-positive breast cancer
par: Li X, et autres
Publié: (2019)

Targeting HER2 genomic alterations in non-small cell lung cancer
par: Jie Zeng, et autres
Publié: (2021)

Novel silk fibroin nanoparticles incorporated silk fibroin hydrogel for inhibition of cancer stem cells and tumor growth
par: Wu P, et autres
Publié: (2018)

The tumor immune microenvironment of primary and metastatic HER2− positive breast cancers utilizing gene expression and spatial proteomic profiling
par: Ilana Schlam, et autres
Publié: (2021)

Enhancing Antitumor Efficacy of Nucleoside Analog 5-Fluorodeoxyuridine on HER2-Overexpressing Breast Cancer by Affibody-Engineered DNA Nanoparticle
par: Zhang C, et autres
Publié: (2020)

A Triptolide Loaded HER2-Targeted Nano-Drug Delivery System Significantly Suppressed the Proliferation of HER2-Positive and BRAF Mutant Colon Cancer
par: Yalikong A, et autres
Publié: (2021)

Effectiveness and safety of pyrotinib‐based therapy in patients with HER2‐positive metastatic breast cancer: A real‐world retrospective study
par: Chao Li, et autres
Publié: (2021)

Twist1 Influences the Expression of Leading Members of the IL-17 Signaling Pathway in HER2-Positive Breast Cancer Cells
par: Bruno R. B. Pires, et autres
Publié: (2021)

Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site
par: Lower EE, et autres
Publié: (2017)

The Pseudokinase TRIB3 Negatively Regulates the HER2 Receptor Pathway and Is a Biomarker of Good Prognosis in Luminal Breast Cancer
par: Alba Orea-Soufi, et autres
Publié: (2021)

Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides
par: Shushan Ge, et autres
Publié: (2021)

AMPD1 Is Associated With the Immune Response and Serves as a Prognostic Marker in HER2-Positive Breast Cancer
par: Long Wang, et autres
Publié: (2021)

<sup>1</sup>H-NMR Plasma Lipoproteins Profile Analysis Reveals Lipid Metabolism Alterations in HER2-Positive Breast Cancer Patients
par: Giuseppe Corona, et autres
Publié: (2021)

Intratumoral Heterogeneity and Immune Response Indicators to Predict Overall Survival in a Retrospective Study of HER2-Borderline (IHC 2+) Breast Cancer Patients
par: Gedmante Radziuviene, et autres
Publié: (2021)

Liposomes derivatized with multimeric copies of KCCYSL peptide as targeting agents for HER-2-overexpressing tumor cells
par: Ringhieri P, et autres
Publié: (2017)

Heart Failure Therapies for the Prevention of HER2-Monoclonal Antibody-Mediated Cardiotoxicity: A Systematic Review and Meta-Analysis of Randomized Trials
par: Lauren J. Brown, et autres
Publié: (2021)

Disparities in Guideline-Concordant Initial Systemic Treatment in Women with HER2-Negative Metastatic Breast Cancer: A SEER-Medicare Analysis
par: Vyas A, et autres
Publié: (2021)

The Role of Trastuzumab in Patients with HER2 Positive Small (pT1mi/a) Breast Cancers, a Multicenter Retrospective Study
par: Andrea Villasco, et autres
Publié: (2021)

Housekeeping gene as a source of calibrator candidate for HER-2 scoring in frozen tissue breast cancer study based on qPCR
par: RISMAYA RISMAYA, et autres
Publié: (2017)

Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer
par: Matteo Allegretti, et autres
Publié: (2021)

Clinical Characteristics and Prognosis of HER2 Gene Phenotype in Patients with Non-Small Cell Lung Cancer
par: Diao WY, et autres
Publié: (2021)

Single-day HER2neu amplification assessment using chip-based digital PCR in formalin-fixed paraffin-embedded breast carcinoma tissue
par: Shah PS, et autres
Publié: (2018)

Down-Regulation of USP8 Suppresses HER-3 Positive Gastric Cancer Cells Proliferation [Corrigendum]
par: Sun J, et autres
Publié: (2021)

2D-echocardiography vs cardiac MRI strain: a prospective cohort study in patients with HER2-positive breast cancer undergoing trastuzumab
par: Nathalie I. Bouwer, et autres
Publié: (2021)

The EGF Domains of MUC4 Oncomucin Mediate HER2 Binding Affinity and Promote Pancreatic Cancer Cell Tumorigenesis
par: Nicolas Stoup, et autres
Publié: (2021)

Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer
par: Azar I, et autres
Publié: (2021)